John Whitney, MD
Family Medicine · South Bend, INNPI 1205240637
Payments from drug & device makers
Across 170 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$478
- AstraZeneca$235
- Vifor Pharma, Inc.$201
- Novo Nordisk$199
- Pfizer$150
- GSK$147
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $478 |
| AstraZeneca | 15 | $235 |
| Vifor Pharma, Inc. | 9 | $201 |
| Novo Nordisk | 15 | $199 |
| Pfizer | 14 | $150 |
| GSK | 18 | $147 |
| Novartis | 11 | $142 |
| Amgen(2 entities) | 9 | $134 |
| Bayer | 7 | $119 |
| Boehringer Ingelheim | 6 | $91 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $42 |
| Johnson & Johnson | 3 | $39 |
| Lilly USA, LLC | 3 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Mylan Specialty L.p. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Fresenius USA Marketing, Inc. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Exact Sciences | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Neos Therapeutics, LP | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Covis Pharma GmbH | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
How this compares
$2,609 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $158,392 |
| EliquisApixaban | 74 | $83,370 |
| JardianceEmpagliflozin | 29 | $44,103 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $29,794 |
| FarxigaDapagliflozin Propanediol | 23 | $28,892 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $25,042 |
| MounjaroTirzepatide | 12 | $20,606 |
| XareltoRivaroxaban | 15 | $17,964 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $14,323 |
| LinzessLinaclotide | 11 | $10,184 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,087 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $8,392 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $5,970 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,561 |
| Atorvastatin Calcium | 467 | $3,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $199 | $158,392128 claims |
| PfizerEliquis | $150 | $83,37074 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $91 | $58,42642 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $147 | $54,83650 claims |
| AstraZenecaFarxiga, Symbicort | $235 | $32,47335 claims |
| Lilly USA, LLCMounjaro | $35 | $20,60612 claims |
| Johnson & JohnsonXarelto | $39 | $17,96415 claims |
| AbbVieLinzess, Synthroid | $478 | $11,16427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in South Bend
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.